{{Drugbox
| IUPAC_name = 1-(3-Chlorophenyl)-4-[2-(5-methyl-1''H''-pyrazol-3-yl)ethyl]piperazine
| image = Mepiprazole structure.svg

<!--Clinical data-->
| tradename = Psigodal
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 20326-12-9
| CAS_supplemental = <br />20344-15-4 ([[hydrochloride]])
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 71897
| ChemSpiderID = 64909
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 977BAL0NR7
| synonyms = PAP, EMD-16923, H-4007

<!--Chemical data-->
| C=16 | H=21 | Cl=1 | N=4 
| molecular_weight = 304.82 g/mol
| smiles = Clc3cccc(N2CCN(CCc1nnc(c1)C)CC2)c3
}}

'''Mepiprazole''' ([[International Nonproprietary Name|INN]], [[British Approved Name|BAN]]) (brand name '''Psigodal''') is an [[anxiolytic]] [[drug]] of the [[phenylpiperazine]] group with additional [[antidepressant]] properties<ref name="pmid9660" /> that is marketed in [[Spain]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA768|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=768–}}</ref><ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | pages = | isbn = 3-88763-075-0 | oclc = | doi = | url = https://books.google.com/books?id=5GpcTQD_L2oC&lpg=PA648&dq=mepiprazole&pg=PA648#v=onepage&q&f=false}}</ref><ref name="pmid1095510">{{cite journal | author = Pöldinger W | title = Clinical trial of 3-methyl-5-(beta-N'-(N-m-chlorophenylpiperazino)ethyl)-pyrazole dihydrochloride (Mepiprazol) in the therapy of psychovegetative disorders | journal = International Pharmacopsychiatry | volume = 10 | issue = 1 | pages = 1–8 | year = 1975 | pmid = 1095510 | doi = | url = }}</ref><ref name="pmid769484">{{cite journal |vauthors=De Buck R, Van Durme R, Pelc I | title = [A controlled double-blind crossover study of the efficacy of mepiprazol (EMD 16.923) and of diazepam in the treatment of neurotic disorders] | language = French | journal = Acta Psychiatrica Belgica | volume = 75 | issue = 3 | pages = 320–33 |date=May 1975 | pmid = 769484 | doi = | url = }}</ref><ref name="pmid1052713">{{cite journal |vauthors=Saldaña Hernández OH, Hernández González J | title = [Psychopharmological research with EMD 16-923 in patients with different degrees of anxiety] | language = Spanish| journal = Neurología, Neurocirugía, Psiquiatría | volume = 17 | issue = 1 | pages = 29–33 | year = 1976 | pmid = 1052713 | doi = | url = }}</ref> It acts as a [[5-HT2A receptor|5-HT<sub>2A</sub>]] and [[alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic receptor]] [[receptor antagonist|antagonist]]<ref name="pmid6311738">{{cite journal |vauthors=Cohen ML, Fuller RW, Kurz KD | title = Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats | journal = Hypertension | volume = 5 | issue = 5 | pages = 676–81 | year = 1983 | pmid = 6311738 | doi = 10.1161/01.hyp.5.5.676| url = http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=6311738}}</ref><ref name="pmid7255266">{{cite journal |vauthors=Maj J, Sypniewska M | title = Central action of mepiprazole | journal = Polish Journal of Pharmacology and Pharmacy | volume = 32 | issue = 4 | pages = 475–84 | year = 1980 | pmid = 7255266 | doi = | url = }}</ref><ref name="pmid943291">{{cite journal |vauthors=Fuxe K, Agnati LF, Ungerstedt U | title = The effect of mepiprazole on central monoamine neurons. Evidence for increased 5-hydroxytryptamine and dopamine receptor activity | journal = European Journal of Pharmacology | volume = 35 | issue = 1 | pages = 93–108 |date=January 1976 | pmid = 943291 | doi = 10.1016/0014-2999(76)90304-6| url = }}</ref> and [[reuptake inhibitor|inhibit]]s the [[reuptake]] and induces the [[releasing agent|release]] of [[serotonin]], [[dopamine]], and [[norepinephrine]] to varying extents,<ref name="pmid9660">{{cite journal |vauthors=Placheta P, Singer E, Kriwanek W, Hertting G | title = Mepiprazole, a new psychotropic drug: effects on uptake and retention of monoamines in rat brain synaptosomes | journal = Psychopharmacology | volume = 48 | issue = 3 | pages = 295–301 |date=August 1976 | pmid = 9660 | doi = 10.1007/BF00496865| url = }}</ref><ref name="pmid943291" /> and has been described as a [[serotonin antagonist and reuptake inhibitor]] (SARI).<ref name="FagioliniComandini2012">{{cite journal|last1=Fagiolini|first1=Andrea|last2=Comandini|first2=Alessandro|last3=Dell’Osso|first3=Mario Catena|last4=Kasper|first4=Siegfried|title=Rediscovering Trazodone for the Treatment of Major Depressive Disorder|journal=CNS Drugs|volume=26|issue=12|year=2012|pages=1033–1049|issn=1172-7047|doi=10.1007/s40263-012-0010-5|pmid=23192413|pmc=3693429}}</ref> Controlled clinical trials of mepiprazole in patients with [[irritable bowel syndrome]] (IBS) were also carried out and suggested some benefits of the drug in relieving symptoms of IBS in some patients.<ref name="pmid4609545">{{cite journal |vauthors=Dotevall G, Groll E | title = Controlled clinical trial of mepiprazole in irritable bowel syndrome | journal = The British Medical Journal | volume = 4 | issue = 5935 | pages = 16–8 |date=October 1974 | pmid = 4609545 | doi = 10.1136/bmj.4.5935.16| pmc=1612118}}</ref>  Similarly to other phenylpiperazines like [[trazodone]], [[nefazodone]], and [[etoperidone]], mepiprazole produces [[meta-Chlorophenylpiperazine|''m''CPP]] as an [[active metabolite]].<ref name="pmid6128394">{{cite journal |vauthors=Fong MH, Garattini S, Caccia S | title = 1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole | journal = The Journal of Pharmacy and Pharmacology | volume = 34 | issue = 10 | pages = 674–5 |date=October 1982 | pmid = 6128394 | doi = 10.1111/j.2042-7158.1982.tb04701.x| url = }}</ref>

==See also==
* [[Acaprazine]]
* [[Enpiprazole]]
* [[Lorpiprazole]]
* [[Tolpiprazole]]

==References==
{{reflist|30em}}

{{Anxiolytics}}
{{Adrenergic receptor modulators}}
{{Serotonin receptor modulators}}
{{Monoamine releasing agents}}
{{Piperazines}}

[[Category:5-HT2A antagonists]]
[[Category:Alpha-1 blockers]]
[[Category:Chloroarenes]]
[[Category:Piperazines]]
[[Category:Pyrazoles]]
[[Category:Serotonin-norepinephrine-dopamine releasing agents]]


{{Nervous-system-drug-stub}}